Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00448_DB00758_nanopub.RAO45Od3QLRORy0qI1c8_Y6vi4dKqykWDPHDtwu4FcDhE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00448_DB00758 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00448_DB00758 label "DDI between Lansoprazole and Clopidogrel - Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. [drugbank_resource:DB00448_DB00758]" assertion.
- drugbank_resource:DB00448_DB00758 identifier "drugbank_resource:DB00448_DB00758" assertion.
- drugbank_resource:DB00448_DB00758 title "DDI between Lansoprazole and Clopidogrel - Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel." assertion.
- drugbank:DB00758 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00448_DB00758 assertion.
- drugbank:DB00448 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00448_DB00758 assertion.